itprip Antibody

What applications are recommended for anti-ITPRIP antibodies?

Anti-ITPRIP antibodies have been validated for multiple experimental applications:

These applications enable researchers to detect ITPRIP expression, localization, and molecular interactions in various experimental contexts. When designing experiments, consider that antibody performance may vary between applications and require optimization for specific cell types or tissues.

How should ITPRIP antibodies be stored for optimal performance?

For long-term storage, anti-ITPRIP antibodies should be kept at -20°C for up to one year . For frequent use and short-term storage (up to one month), storage at 4°C is recommended . The commercial formulation typically includes PBS with 0.02% sodium azide and 50% glycerol at pH 7.2 . It is critical to avoid repeated freeze-thaw cycles as these can significantly degrade antibody performance through protein denaturation and aggregation. When designing experimental timelines, factor in a thawing period (allowing antibodies to reach room temperature gradually) and consider preparing aliquots to minimize freeze-thaw cycles for rarely used antibodies.

How can researchers differentiate between ITPRIP and ITPRIPL1 in experimental settings?

Distinguishing between ITPRIP and ITPRIPL1 requires careful antibody selection and experimental controls:

• Antibody epitope verification: Select antibodies targeting unique regions - for example, anti-ITPRIPL1 antibodies targeting amino acids 43-71 in the N-terminal region versus anti-ITPRIP antibodies targeting different epitopes.

• Knockout validation: Perform validation using knockout models. Research has demonstrated the specificity of anti-ITPRIPL1 antibodies using ITPRIPL1−/− mice, where the absence of bands in knockout samples confirmed antibody specificity .

• Cross-reactivity testing: Test antibodies against recombinant proteins of both ITPRIP and ITPRIPL1 to ensure specificity.

• Multiple detection methods: Combine techniques (e.g., Western blot, immunofluorescence, and mass spectrometry) to confirm target identity.

• Transcriptomic correlation: Compare protein detection with mRNA expression data from resources like the Cancer Cell Line Encyclopedia (CCLE) to verify concordance between transcript and protein levels .

What is the significance of ITPRIPL1 in cancer research and how can antibodies facilitate its study?

ITPRIPL1 has emerged as a significant protein in cancer research due to its role as a natural CD3ε ligand that downregulates T cell function and promotes tumor growth . Research has revealed:

• Overexpression pattern: ITPRIPL1 is overexpressed in various human cancer cell lines including melanoma (A375), rhabdomyosarcoma (A-204, RD), non-small cell lung cancer (A549, H1299), breast cancer (MBA-MD-231, MCF7), and colorectal carcinoma (HCT116, SW480, SW1116) .

• Immune evasion mechanism: Cancer cells upregulate ITPRIPL1 as a mechanism to evade immune surveillance, suggesting its role as a novel immune checkpoint .

• Clinical correlation: ITPRIPL1 expression correlates with reduced CD8+ T cell infiltration in non-small cell lung cancer, potentially affecting patient outcomes .

Antibodies facilitate ITPRIPL1 study through:

• Immunohistochemical detection in patient samples

• Flow cytometric analysis of expression levels

• Therapeutic blocking of ITPRIPL1-CD3ε interaction (the 13B7A6H3 clone shows promise in this application)

• Diagnostic applications for cancer detection

What validation strategies should be employed for anti-ITPRIP and anti-ITPRIPL1 antibodies?

Comprehensive validation strategies include:

• Multiple assay validation: Antibodies should be tested across multiple applications (WB, IHC, ICC, IF, ELISA) with known positive and negative samples .

• Genetic models: Testing with knockout models provides the gold standard for specificity. For example, ITPRIPL1 antibody specificity was confirmed using spleen extracts from ITPRIPL1−/− mice compared to wild-type C57BL/6Smoc mice .

• Cell line panel testing: Validation across diverse cell lines with different expression levels helps establish sensitivity limits and confirms detection across a spectrum of expression .

• Purity assessment: Antibody purity should be confirmed through methods like:

  • Coomassie Blue staining (confirming >95% purity)

  • Silver staining for higher sensitivity detection

• Background assessment: Evaluate non-specific binding and background signal, particularly important for immunohistochemistry applications.

• Peptide competition: Blocking peptides can verify epitope specificity by competing with the target protein for antibody binding .

How can anti-ITPRIPL1 antibodies be utilized in immune checkpoint research?

Recent findings have established ITPRIPL1 as part of a novel immune checkpoint controlling T cell activation through CD3ε interaction . Researchers can utilize anti-ITPRIPL1 antibodies in this field through:

• Blocking antibody development: The monoclonal antibody clone 13B7A6H3 (13B7) has shown promise in blocking ITPRIPL1-CD3ε interaction, potentially restoring anti-tumor immunity . This represents a therapeutic approach that researchers can explore in preclinical models.

• Mechanistic studies: Anti-ITPRIPL1 antibodies can help elucidate the molecular mechanisms of how ITPRIPL1 impairs T cell activation through CD3ε binding.

• Tumor microenvironment analysis: Immunohistochemistry with anti-ITPRIPL1 antibodies can reveal expression patterns in relation to immune cell infiltration, particularly CD8+ T cells .

• Companion diagnostics: The correlation between ITPRIPL1 expression and prognosis in cancers like NSCLC suggests potential for companion diagnostic development to identify patients who might benefit from therapies targeting this pathway .

• Combination therapy research: Investigating how ITPRIPL1 blockade might synergize with established checkpoint inhibitors (anti-PD-1/PD-L1, anti-CTLA-4) represents a frontier in immunotherapy research.

What methodological considerations are important when using ITPRIP/ITPRIPL1 antibodies for cancer biomarker studies?

When utilizing these antibodies for biomarker studies, researchers should consider:

• Sample preparation optimization:

  • Tissue fixation conditions significantly impact epitope accessibility

  • Antigen retrieval methods should be optimized (citrate-based buffers are often used)

  • Processing time can affect protein integrity

• Quantitative analysis approaches:

  • Establish scoring systems for immunohistochemistry

  • Use digital pathology tools for objective quantification

  • Include expression thresholds based on clinical correlations

• Control selection:

  • Adjacent normal tissue provides internal controls

  • Include positive and negative control tissues in each batch

  • Consider isotype controls to assess non-specific binding

• Clinical correlation methods:

  • Correlate expression with patient outcomes using Kaplan-Meier analysis

  • Assess relationship with immune infiltrates (particularly CD8+ T cells)

  • Perform multivariate analysis with established prognostic factors

• Technical reproducibility:

  • Standardize protocols across laboratories

  • Use automated staining platforms when possible

  • Implement blinded scoring by multiple pathologists

How can researchers troubleshoot non-specific binding with ITPRIP antibodies?

Non-specific binding is a common challenge when working with antibodies. For ITPRIP antibodies specifically:

• Optimize blocking conditions: Test different blocking agents (BSA, normal serum, commercial blockers) at various concentrations and incubation times.

• Adjust antibody concentration: Titrate the antibody, starting with the recommended dilution range of 1:500-1:2000 for WB and 1:50-1:200 for ICC/IF .

• Modify washing steps: Increase washing duration or frequency, and consider adding detergents like Tween-20 at appropriate concentrations.

• Pre-adsorption: Pre-adsorb the antibody with cell/tissue lysates from species known to give cross-reactivity.

• Validate with knockout/knockdown controls: Use ITPRIP knockout or knockdown samples as negative controls, similar to the validation approach used for ITPRIPL1 antibodies .

• Secondary antibody optimization: Test different secondary antibodies and consider using secondary-only controls to identify background from this source.

• Epitope competition: Use blocking peptides corresponding to the ITPRIP epitope to confirm signal specificity .

What are the best practices for quantitative analysis of ITPRIP/ITPRIPL1 expression in patient samples?

For reliable quantitative analysis:

• Standardized scoring systems:

  • For IHC: Implement H-score (intensity × percentage) or Allred scoring

  • For Western blot: Normalize to housekeeping proteins like β-actin or GAPDH

  • For flow cytometry: Use mean fluorescence intensity (MFI) and clearly defined positive populations

• Reference standards:

  • Include calibration samples with known expression levels

  • Use cell lines with characterized expression as controls

  • Consider recombinant protein standards for absolute quantification

• Image analysis protocols:

  • Use digital pathology software with validated algorithms

  • Establish consistent thresholds for positive staining

  • Perform region-of-interest selection systematically

• Statistical approaches:

  • Define cutoffs for "high" vs. "low" expression based on clinical outcomes

  • Use continuous data when possible to avoid information loss

  • Apply appropriate statistical tests based on data distribution

• Multi-parameter correlation:

  • Correlate with other relevant biomarkers (e.g., CD8+ T cells )

  • Integrate with genomic and clinical data

  • Consider spatial relationships in the tumor microenvironment